Inhibiting ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes

Cancer Research

Volumn 58, Issue 8, 1998, Pages 1754-1761

  Bernhard, Eric J ^a,d   McKenna, W Gillies ^a   Hamilton, Andrew D ^b   Sebti, Said M ^c   Qian, Yimin ^b   Wu, JunMin ^a   Muschel, Ruth J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b YALE UNIVERSITY   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; PRENYLATION; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TUMOR CELL;

BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENES, RAS; HUMANS; METHIONINE; MUTATION; PROTEIN ISOPRENYLATION; PROTO-ONCOGENE PROTEINS P21(RAS); RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0032522849     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. FitzGerald, T. J., Daugherty, C., Kase, K., Rothstein, L. A., McKenna, M., and Greenberger, J. S. Activated human N-ras oncogene enhances x-irradiation repair of mammalian cells in vitro less effectively at low dose rate. Am. J. Clin. Oncol., 8: 517-522, 1985.
2. Sklar, M. D. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science (Washington DC), 239: 645-647, 1988.
3. Pirollo, K., Tong, Y., Villegas, Z., Chen, Y., and Chang, E. Oncogene-transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. Radiat. Res., 135: 234-243, 1993.
4. Samid, D., Miller, A. C., Rimoldi, D., Gafner, J., and Clark, E. P. Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression. Radiat. Res., 126: 244-250, 1991.
5. McKenna, W. G., Weiss, M. A., Bakanauskas, V. J., Sandler, H., Kelsten, M., Biaglow, J., Endlich, B., Ling, C., and Muschel, R. J. The role of the Hras oncogene in radiation resistance and metastasis. Int. J. Radiat. Oncol. Biol. Phys., 18: 849-860, 1990.
6. Ling, C. C., and Endlich, B. Radioresistance induced by oncogenic transformation. Radiat. Res., 120: 267-279, 1989.
7. Hermens, A., and Bentvelzen, P. Influence of the H-ras oncogene on radiation responses of a rat rhabdomyosarcoma cell line. Cancer Res., 52: 3073-3082, 1992.
8. ras isoprenylation. Int. J. Cancer, 53: 302-307, 1993.
9. Miller, A. C., Gafner, J., Clark, E. P., and Samid, D. Differences in radiation-induced micronuclei yields of human cells: influence of ras gene expression and protein localization. Int. J. Radiat. Biol., 64: 547-554, 1993.
10. Bruyneel, E. A., Storme, G. A., Schallier, D. C., Van den Berge, D. L., Hilgard, P., and Mareel, M. M. Evidence for abrogation of oncogene-induced radioresistance of mammary cancer cells by hexadecylphosphocholine in vitro. Eur. J. Cancer, 29A: 1958-1963, 1993.
11. Alapetite, C., Baroche, C., Remvikos, Y., Goubin, G., and Moustacchi, E. Studies on the influence of the presence of an activated ras oncogene on the in vitro radiosensitivity of human mammary epithelial cells. Int. J. Radiat. Biol., 59: 385-396, 1991.
12. Mendonca, M. S., Boukamp, P., Stanbridge, E. J., and Redpath, J. L. The radiosensitivity of human keratinocytes: influence of activated c-H-ras oncogene expression and tumorigenicity. Int. J. Radiat. Biol., 59: 1195-1206, 1991.
13. Su, L-N., and Little, J. B. Transformation and radiosensitivity of human diploid skin fibroblasts transfected with activated RAS oncogene and SV40 T-antigen. Int. J. Radiat. Biol., 62: 201-210, 1992.
14. Glomset, J. A., and Farnsworth, C. C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu. Rev. Cell Biol., 10: 181-205, 1994.
15. Moores, S. L., Schaber, M. D., Mosser, S. D., Rands, E., O'Hara, M. B., Garsky, V. M., Marshall, M. S., Pompliano, D. L., and Gibbs, J. B. Sequence dependence of protein isoprenylation. J. Biol. Chem., 266: 14603-14610, 1991.
16. James, G., Goldstein, J., and Brown, M. Polylysine, and CVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J. Biol. Chem., 270: 6221-6226, 1995.
17. ras protein farnesyltransferase. Proc. Natl. Acad. Sci. USA, 88: 732-736, 1991.
18. Willumsen, B. M., Norris, K., Papageorge, A. G., Hubbert, N. L., and Lowy, D. R. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J., 3: 2581-2585, 1984.
19. Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., and Lowy, D. R. The p21 ras C-terminus is required for transformation and membrane association. Nature (Lond.), 310: 583-586, 1984.
20. Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., and Der, C. J. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc. Natl. Acad. Sci USA, 87: 3042-3046, 1990.
21. Buss, J. E., Solski, P. A., Schaeffer, J. P., MacDonald, M. J., and Der, C. J. Activation of the cellular proto-oncogene product p21ras by addition of a myristylation signal. Science (Washington DC), 243: 1600-1602, 1989.
22. Cox, A. D., Hisaka, M. M., Buss, J. E., and Der, C. J. Specific isoprenoid modification is required for function of normal, but not oncogenic, ras protein. Mol. Cell. Biol., 12: 2606-2615, 1992.
23. Clarke, S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Annu. Rev. Biochem., 61: 355-386, 1992.
24. Gibbs, J., Oliff, A., and Kohl, N. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell, 77: 175-178, 1994.
25. James, G., Brown, M., Cobb, M., and Goldstein, J. Benzodiazepine peptidomimetic BZA-5B interrupts the MAP kinase activation pathway in H-ras-transformed rat-1 cells, but not in untransformed cells. J. Biol. Chem., 209: 27705-27714, 1994.
26. Kohl, N. E., Mosser, S. D., deSolms, S. J., Giuliani, E. A., Pompliano, D. L., Graham, S. L., Smith, R. L., Scolnick, E. M., Orliff, A., and Gibbs, J. B. Selective inhibition of ras dependent transformation by a farnesyltransferase inhibitor. Science (Washington DC), 260: 1934-1936, 1993.
27. Qian, Y., Blaskovich, M. A., Saleem, M., Seong, C. M., Wathen, S. P., Hamilton, A. D., and Sebti, S. M. Design and structural requirements of potent peptidomimetic inhibitors of p21 ras farnesyltransferase. J. Biol. Chem., 269: 12410-12413, 1994.
28. Prendergast, G., Davide, J., deSolms, S., Giuliani, E., Graham, S., Gibbs, J., Oliff, A., and Kohl, N. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol., 14: 4193-4202, 1994.
29. Cox, A., Garcia, A., Westwick, J., Kowalczyk, J., Lewis, M., Brenner, D., and Der, C. The CAAX peptidomimetic compound B581 specifically blocks farnesylated, but not geranylgeranylated or myristylated, oncogenic ras signaling and transformation. J. Biol. Chem., 269: 19203-19206, 1994.
30. Trueblood, C. E., Ohya, Y., and Rine, J. Genetic evidence for in vivo cross-specificity of the CaaX-box protein prenyltransferases farnesyltransferase and geranylgeranyltransferase-I in Saccharomyces cerevisiae. Mol. Cell. Biol., 13: 4260-4275, 1993.
31. Yokoyama, K., Goodwin, G. W., Ghomashchi, F., Glomset, J. A., and Gelb, M. H. A protein geranylgeranyltransferase from bovine brain: implications for protein prenylation specificity. Proc. Natl. Acad. Sci. USA, 88: 5302-5306, 1991.
32. Bernhard, E. J., Kao, G., Cox, A. D., Sebti, S. M., Hamilton, A. D., Muschel, R. J., and McKenna, W. G. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. Cancer Res., 56: 1727-1730, 1996.
33. McKenna, W. G., Weiss, M. C., Endlich, B., Ling, C. C. Bakanauskas, V. J., Kelsten, M. L., and Muschel, R. J. Synergistic effect of the v-myc oncogene with Hras on radioresistance. Cancer Res., 50: 97-102, 1990.
34. Lerner, E., Qian, Y., Blaskovich, M., Fossum, R. D., Vogt, A., Sun, J., Cox, A., Der, C., Hamilton, A., and Sebti, S. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic ras signalling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J. Biol. Chem., 270: 26802-26806, 1995.
35. Vogt, A., Qian, Y., Blaskovich, M. A., Fossum, R. D., Hamilton, A. D., and Sebti, S. M. A non-peptide mimetic of ras-CAAX: selective inhibition of farnesyltransferase and ras processing. J. Biol. Chem., 270: 660-664, 1995.
36. Lerner, E., Qian, Y., Hamilton, A., and Sebti, S. Disruption of oncogenic K-ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor. J. Biol. Chem., 270: 26770-26773, 1995.
37. McGuire, T. F., Qian, Y., Vogt, A., Hamilton, A. D., and Sebti, S. M. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation. J. Biol. Chem., 271: 27402-27407, 1996.
38. Vogt, A., Qian, Y., McGuire, T. F., Hamilton, A. D., and Sebti, S. M. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts. Oncogene, 13: 1991-1999, 1996.
39. Kohl, N., Omer, C. Connor, M., Anthony, N., Davide, J., Desolms, S., Giuliani, E., Gomez, R., Graham, S., Hamilton, K., Handt, L., Hartman, G., Koblan, K., Kral, A., Miller, P., Mosser, S., O'Neill, T., Rands, E., Schaber, M., Gibbs, J., and Oliff, A. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat. Med., 1: 792-797, 1995.
40. Henkel, A. W., and Bieger, S. C. Quantification of proteins dissolved in an electrophoresis sample buffer. Anal. Biochem., 223: 329-331, 1994.
41. Lefkovits, I. Limiting dilution analysis. Immunol. Methods, 1: 355-370, 1979.
42. Thilly, W. G., DeLuca, J. G., Furth, E. E., Hoppe, H. L. Kaden, D. A., Krolewski, J. J., Liber, H. L., Skopek, T. R., Slapikoff, S. A., Tizard, R. J., and Penman, B. W. Gene-locus mutation analysis in diploid human lymphoblast lines. In: F. J. d. Serres and A. Hollaender (eds.), Chemical Mutagens, Vol. 6, pp. 331-364. New York: Plenum Publishing Corp., 1980.
43. Grenman, R., Burk, D., Virolainen, E., Buick, R. N., Church, J., and Schwartz, D. R. Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution. Int. J. Cancer, 44: 131-136, 1989.
44. Lebowitz, P. F., Davide, J. P., and Prendergast, G. C. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity. Mol. Cell. Biol., 15: 6613-6622, 1995.
45. Lebowitz, P. F., Casey, P. J., Prendergast, G. C., and Thissen, J. A. Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem., 272: 15591-15594, 1997.
46. WAF1/CIP1/SDI1 in a p53-independent manner. J. Biol. Chem., 272: 27224-27229, 1997.
47. 2-M enrichment in A549 cells. Cancer Res., 57: 1846-1850, 1997.
48. Czerniak, B., Cohen, G. L., Etkind, P., Deitch, D., Simmons, H., Herz, F., and Koss, L. G. Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas. Hum. Pathol., 23: 1199-1204, 1992.
49. Lemoine, N. R., Mayall, E. S., Wyllie, F. W., Williams, E. D., Goyns, M., Stringer, B., and Wynford-Thomas, D. High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene, 4: 159-164, 1989.
50. Anderson, J. A., Irish, J. C., and Ngan, B. Y. Prevalence of ras oncogene mutation in head and neck carcinomas. J. Otolaryngol., 21: 321-326, 1992.
51. Wilke, W., Maillet, M., and Robinson, R. H-ras-1 point mutations in soft tissue sarcomas. Mod. Pathol., 21: 129-132, 1993.
52. Bohle, R. M., Brettreich, S., Repp, R., Borkhardt, A., Kosmehl, H., and Altmannsberger, H. M. Single somatic ras gene point mutation in soft tissue malignant fibrous histiocytomas. Am. J. Pathol., 148: 731-738, 1996.
53. Konishi, N., Hiasa, Y., Matsuda, H., Tao, M., Tsuzuki, T., Hayashi, I., Kitahori, Y., Shiraishi, T., Yatani, R., Shimazaki, J., and Lin, J-C. Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am. J. Pathol., 147: 1112-1122, 1995.
54. Watanabe, M., Shiraishi, T., Yatani, R., Nomura, A. M., and Stemmermann, G. N. International comparison on ras gene mutation in latent prostate carcinoma. Int. J. Cancer, 58: 174-178, 1994.
55. Riou, G., Barrois, M., Sheng, Z. M., Duvillard, P., and Lhomme, C. Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene, 3: 329-333, 1988.
56. Smit, V. T. H. B. M., Boot, A. J. M., Smits, A. M. M., Fleuren, G. J., Cornelisse, C. J., and Bos, J. L. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res., 16: 7773-7782, 1988.
57. Capella, G., Cronauer-Mitra, S., Pienado, M. A., and Perucho, M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ. Health Perspect., 93: 125-131, 1991.
58. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M. M., and Bos, J. L. Genetic alterations during colorectal-tumor development. N. Engl. J. Med., 319: 525-532, 1988.
59. Husgafvel-Pursiainen, K., Ridanpaa, M., Anttila, S., and Vainio, H. p53 and ras gene mutations in lung cancer: implications for smoking and occupational exposures. J. Occup. Environ. Med., 37: 69-76, 1995.
60. Symonds, R. P., Habeshaw, T., Paul, J., Kerr, D. J., Darling, A., Burnett, R. A., Sotsiou, F., Linardopolus, S., and Spandidos, D. A. No correlation between ras, c-myc and c-jun proto-oncogene expression and prognosis in advanced carcinoma of the cervix. Eur. J. Cancer, 28A: 1615-1617, 1992.
61. Hiwasa, T., Hirono, M., Suzuki, M., and Tanaka, T. Expression and localization of epidermal growth factor receptors and ras oncogene products in gynecologic tumors. Eur. J. Gynaecol. Oncol., 13: 241-245, 1992.
62. Lerner, E. C., Zhang, T-T., Knowles, D. B., Qian, Y., Hamilton, A. D., and Sebti, S. M. Inhibition of the prenylation of K-ras, but not H-or N-ras, is highly resistant to CAAX peptidomimetics and requires both a famesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene, 15: 1283-1288, 1997.
63. Taparowsky, E., Suard, Y., Fasano, O., Shimizu, K., Goldfarb, M., and Wigler, M. Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. Nature (Lond.), 300: 762-765, 1982.
64. Tabin, C. J., Bradley, S. M., Bargmann, C. I., Weinberg, R. A., Papageorge, A. G., Scolnick, E. M., Dhar, R., Lowy, D. R., and Chang, E. H. Mechanism of activation of a human oncogene. Nature (Lond.), 300: 143-149, 1982.
65. Kraus, M., Yuasa, Y., and Aaronson, S. A position 12-activated H-ras oncogene in all HS578T mammary carcinoma cells but not in normal mammary cells of the same patient. Proc. Natl. Acad. Sci. USA, 81: 5384-5388, 1984.
66. Leibovitz, A., Stinson, J. C., McCombs, W. B., McCoy, C. E., Mazur, K. C., and Mabry, N. D. Classification of human colorectal adenocarcinoma cell lines. Cancer Res., 16: 4562-4569, 1976.
67. Slebos, R. J. C., Habets, G. G. M., Evers, S. G., Mooi, W. J., and Rodenhuis, S. Allele specific detection of K-ras oncogene expression in human non-small-cell lung carcinomas. Int. J. Cancer, 48: 51-56, 1991.
68. Hay, R., Caputo, J., Chen, T. R., Macy, M., McClintock, P., and Reid, Y. Catalogue of Cell Lines and Hybridomas, Ed. 7. Rockville, MD: American Type Culture Collection, 1992.
69. von Kleist, S., Chany, E., Burtin, P., King, M., and Fogh, J. Immunohistology of the antigenic pattern of a continuous cell line from a human colon tumor. J. Natl. Cancer Inst., 55: 555-560, 1975.
70. Puck, T. T., Marcus, P. I., and Cieciura, S. J. Clonal growth of mammalian cells in vitro. Growth characteristics of colonies from single HeLa cells with and without a "feeder" layer. J. Exp. Med., 103: 273-284, 1956.